---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-004747"
form_type: "8-K"
ticker: "PMDI"
cik: "0000806517"
company_name: "PSYCHEMEDICS CORP"
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:54:44.303653+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Psychemedics Q2 revenue down 15% to $4.7M; net loss widens to $0.14/sh

## Summary
- Q2 2024 revenue $4.7M vs $5.5M YoY (-15%); net loss $0.8M ($0.14/sh) vs $0.7M ($0.13/sh).
- H1 2024 revenue $10.1M vs $11.4M YoY (-12%); net loss $1.5M ($0.26/sh) vs $1.1M ($0.19/sh).
- CEO cites continued lower client hiring as primary driver of revenue decline.
- Company adjusting operating costs while seeking new markets and applications.

## SEC filing metadata
- accession: 0001171843-24-004747
- form_type: 8-K
- ticker: PMDI
- cik: 0000806517
- company_name: PSYCHEMEDICS CORP
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/806517/000117184324004747/0001171843-24-004747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/806517/000117184324004747/f8k_081324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-004747
- JSON: https://secwatch.observer/filing/0001171843-24-004747.json
- Plain text: https://secwatch.observer/filing/0001171843-24-004747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.